Comparing Intermediate-dose CTX+ G-CSF Plus or Not rhTPO for PB CD34+ Cells Mobilization in MM Patients

• Status: Unknown status
• Trial end date: 2018-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Comparing intermediate-dose CTX (ID-CTX)and G-CSF with rhTPO or without for peripheral blood stem cell mobilization in patients with multiple myeloma, try to find out whether rhTPO combined to ID-CTX + G-CSF could improve the results of peripheral blood stem cell mobilization.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wang Guorong
• Treatments: Cyclophosphamide

Criteria

Inclusion Criteria:

• Diagnosed MM fulfill the International Myeloma Working Group (IMWG) criteria for MM diagnosis

• Eastern Cooperative Oncology Group (ECOG) performance status smaller than 2 and a life expectancy of more than 6 months

• Age at least 18 ys , no more than 70 ys old

• No active infectious disease; no severe organ failure (except renal failure secondary to MM)

• All screening procedures and evaluations should be completed

• All patients should provide written informed consent.

Exclusion Criteria:

1. severe impaired liver function; HIV positive or had active hepatitis A, B or C infection; hepatitis B virus-DNA more than 10^4/L;aspartate aminotransferase ( AST) and alanine aminotransferase (ALT) more than 2.5 upper limit of normal (ULN)

2. any disease that could put patients at high risk, including but not limited to unstable cardiac disease, defined as myocardial infarction in the previous 6 months, New York Heart Association (NYHA) class III-IV heart failure, uncontrolled atrial fibrillation or hypertension

3. severe prior thrombosis-event

4. history of other malignancy, unless cured for more than 3 years

5. pregnancy, lactation or disagreement to take contraceptive measures

6. severe infectious disease (uncured tuberculosis, pulmonary aspergillosis)

7. epilepsia, dementia or any mental disease requiring treatment.